China Animal Husbandry Industry Co Ltd
SSE:600195
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/OCF
Enterprise Value to Operating Cash Flow (EV/OCF) ratio compares a company`s total enterprise value to its operating cash flow. It shows how much investors are paying for each dollar of the company`s operating cash flow, including both equity and debt.
Enterprise Value to Operating Cash Flow (EV/OCF) ratio compares a company`s total enterprise value to its operating cash flow. It shows how much investors are paying for each dollar of the company`s operating cash flow, including both equity and debt.
Valuation Scenarios
If EV/OCF returns to its 3-Year Average (23.2), the stock would be worth ¥17.71 (134% upside from current price).
| Scenario | EV/OCF Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 9.9 | ¥7.58 |
0%
|
| 3-Year Average | 23.2 | ¥17.71 |
+134%
|
| 5-Year Average | 28.4 | ¥21.68 |
+186%
|
| Industry Average | 23.8 | ¥18.16 |
+140%
|
| Country Average | 20.8 | ¥15.89 |
+110%
|
Forward EV/OCF
Today’s price vs future operating cash flow
Peer Comparison
| Market Cap | EV/OCF | P/E | ||||
|---|---|---|---|---|---|---|
| CN |
|
China Animal Husbandry Industry Co Ltd
SSE:600195
|
7.7B CNY | 9.9 | 36.1 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
835.2B USD | 51.5 | 40.3 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
547.8B USD | 23.3 | 25.9 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 15.2 | 20.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
216.4B GBP | 21.1 | 28.1 | |
| CH |
|
Novartis AG
SIX:NOVN
|
218.2B CHF | 15.2 | 19.6 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
276.9B USD | 18.7 | 15.1 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 936 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.2T DKK | 10.5 | 11.4 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
153.5B USD | 17.2 | 19.7 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
118.2B USD | 10.6 | 16.6 |
Market Distribution
| Min | 0 |
| 30th Percentile | 11.5 |
| Median | 20.8 |
| 70th Percentile | 39.2 |
| Max | 266 666.7 |
Other Multiples
China Animal Husbandry Industry Co Ltd
Glance View
China Animal Husbandry Industry Co Ltd. (CAHI) is a compelling narrative of innovation and integration in the agricultural sector, deeply rooted in its mission to uphold food security and safety. As an integral part of the animal husbandry landscape, CAHI wields a strategic mix of agricultural science and technology, producing a diverse portfolio of products ranging from animal feed to veterinary drugs and vaccines. This vertically integrated approach allows the company to control and optimize each stage of the production process. By doing so, CAHI not only ensures the quality and reliability of its products but also maximizes its operational efficiencies. The company's facilities operate at the forefront of technology, leveraging advancements to develop solutions that boost livestock health and farmer productivity, addressing the growing food demand in China and internationally. Revenue streams for CAHI are robust, stemming from its diversified product lineup designed to cater to the entire spectrum of the animal farming industry. The company monetizes its expertise through the sale of feed additives, veterinary pharmaceuticals, and biological products, which are crucial inputs for livestock farmers aiming to enhance productivity and safeguard their herds against diseases. Beyond just selling products, CAHI's value proposition includes extensive after-sales services and technical support, differentiating itself from competitors. By continuously investing in research and development, CAHI sustains its growth trajectory, adapting to regulatory shifts and consumer preferences while positioning itself as a leader in the global market for animal husbandry solutions. This combination of innovation, integration, and customer-focused services anchors CAHI's business model and drives its profitability.